Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Drug interactions and pharmacogenomics in the treatment of breast cancer and depression.

× No keyword cloud information.

33 in total

1. Clinical update: new treatments for hot flushes.

Authors: Vered Stearns
Journal: Lancet Date: 2007-06-23 Impact factor: 79.321

2. Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment.

Authors: Silvana Borges; Zeruesenay Desta; Lang Li; Todd C Skaar; Bryan A Ward; Anne Nguyen; Yan Jin; Anna Maria Storniolo; D Michele Nikoloff; Lin Wu; Grant Hillman; Daniel F Hayes; Vered Stearns; David A Flockhart
Journal: Clin Pharmacol Ther Date: 2006-07 Impact factor: 6.875

3. Duloxetine is both an inhibitor and a substrate of cytochrome P4502D6 in healthy volunteers.

Authors: Michael H Skinner; Han-Yi Kuan; Alan Pan; Korbtham Sathirakul; Mary Pat Knadler; Celedon R Gonzales; Kwee Poo Yeo; Shobha Reddy; Maggie Lim; Mosun Ayan-Oshodi; Stephen D Wise
Journal: Clin Pharmacol Ther Date: 2003-03 Impact factor: 6.875

4. Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patients.

Authors: Susan A Nowell; Jiyoung Ahn; James M Rae; Joshua O Scheys; Andrew Trovato; Carol Sweeney; Stewart L MacLeod; Fred F Kadlubar; Christine B Ambrosone
Journal: Breast Cancer Res Treat Date: 2005-06 Impact factor: 4.872

5. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study.

Authors: Bernard Fisher; Joseph P Costantino; D Lawrence Wickerham; Reena S Cecchini; Walter M Cronin; Andre Robidoux; Therese B Bevers; Maureen T Kavanah; James N Atkins; Richard G Margolese; Carolyn D Runowicz; Joan M James; Leslie G Ford; Norman Wolmark
Journal: J Natl Cancer Inst Date: 2005-11-16 Impact factor: 13.506

6. Phase III, placebo-controlled trial of three doses of citalopram for the treatment of hot flashes: NCCTG trial N05C9.

Authors: Debra L Barton; Beth I LaVasseur; Jeff A Sloan; Allen N Stawis; Kathleen A Flynn; Missy Dyar; David B Johnson; Pamela J Atherton; Brent Diekmann; Charles L Loprinzi
Journal: J Clin Oncol Date: 2010-05-24 Impact factor: 44.544

Review 7. Selective serotonin reuptake inhibitors and cytochrome P-450 mediated drug-drug interactions: an update.

Authors: Alex Hemeryck; Frans M Belpaire
Journal: Curr Drug Metab Date: 2002-02 Impact factor: 3.731

8. Phase III evaluation of fluoxetine for treatment of hot flashes.

Authors: Charles L Loprinzi; Jeff A Sloan; Edith A Perez; Susan K Quella; Phillip J Stella; James A Mailliard; Michele Y Halyard; Sandhya Pruthi; Paul J Novotny; Teresa A Rummans
Journal: J Clin Oncol Date: 2002-03-15 Impact factor: 44.544

9. Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine.

Authors: Vered Stearns; Michael D Johnson; James M Rae; Alan Morocho; Antonella Novielli; Pankaj Bhargava; Daniel F Hayes; Zeruesenay Desta; David A Flockhart
Journal: J Natl Cancer Inst Date: 2003-12-03 Impact factor: 13.506

10. Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients.

Authors: Pia Wegman; Linda Vainikka; Olle Stål; Bo Nordenskjöld; Lambert Skoog; Lars-Erik Rutqvist; Sten Wingren
Journal: Breast Cancer Res Date: 2005-01-28 Impact factor: 6.466

24 in total

1. Relapse after switching antidepressants because of tamoxifen use: a report of 2 cases.

Authors: Adam Keller Ashton
Journal: Prim Care Companion CNS Disord Date: 2011

Review 2. Psychopharmacology in psycho-oncology.

Authors: Rosangela Caruso; Luigi Grassi; Maria Giulia Nanni; Michelle Riba
Journal: Curr Psychiatry Rep Date: 2013-09 Impact factor: 5.285

Review 3. Breast cancer survivorship: a comprehensive review of long-term medical issues and lifestyle recommendations.

Authors: Balazs I Bodai; Phillip Tuso
Journal: Perm J Date: 2015

Review 4. Effect of age on drug metabolism in women with breast cancer.

Authors: Jasmeet C Singh; Stuart M Lichtman
Journal: Expert Opin Drug Metab Toxicol Date: 2015-05 Impact factor: 4.481

5. Trends in co-prescribing of antidepressants and tamoxifen among women with breast cancer, 2004-2010.

Authors: Stacie B Dusetzina; G Caleb Alexander; Rachel A Freedman; Haiden A Huskamp; Nancy L Keating
Journal: Breast Cancer Res Treat Date: 2012-11-13 Impact factor: 4.872

Review 6. Alterations of chemotherapeutic pharmacokinetic profiles by drug-drug interactions.

Authors: Sridhar Mani; Mohammed Ghalib; Imran Chaudhary; Sanjay Goel
Journal: Expert Opin Drug Metab Toxicol Date: 2009-02 Impact factor: 4.481

7. Postgraduate corner: Continuing medical education: Psychopharmacology.

Authors: Chittaranjan Andrade
Journal: Indian J Psychiatry Date: 2009 Jul-Sep Impact factor: 1.759

8. Management of hot flashes in women with breast cancer.

Authors: L Kligman; J Younus
Journal: Curr Oncol Date: 2010-02 Impact factor: 3.677

9. Pharmacogenetics in American Indian populations: analysis of CYP2D6, CYP3A4, CYP3A5, and CYP2C9 in the Confederated Salish and Kootenai Tribes.

Authors: Alison Fohner; LeeAnna I Muzquiz; Melissa A Austin; Andrea Gaedigk; Adam Gordon; Timothy Thornton; Mark J Rieder; Mark A Pershouse; Elizabeth A Putnam; Kevin Howlett; Patrick Beatty; Kenneth E Thummel; Erica L Woodahl
Journal: Pharmacogenet Genomics Date: 2013-08 Impact factor: 2.089

Review 10. PharmGKB summary: tamoxifen pathway, pharmacokinetics.

Authors: Daniel J Klein; Caroline F Thorn; Zeruesenay Desta; David A Flockhart; Russ B Altman; Teri E Klein
Journal: Pharmacogenet Genomics Date: 2013-11 Impact factor: 2.089